<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01993511</url>
  </required_header>
  <id_info>
    <org_study_id>SHJNBJ-FX10</org_study_id>
    <nct_id>NCT01993511</nct_id>
  </id_info>
  <brief_title>Changes in Glucose Metabolism After Roux-en-Y Gastric Bypass</brief_title>
  <official_title>Changes in Glucose Metabolism After Roux-en-Y Gastric Bypass</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hvidovre University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hvidovre University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Besides causing weight loss Roux-en-Y gastric bypass (RYGB) has profound effect on glucose
      metabolism leading to remission of type 2 diabetes early after surgery. However the
      mechanisms for this improvement remain uncertain. The aim of this study is to investigate the
      changes in insulin sensitivity and beta-cell function 1 week and 3 months following RYGB
      using oral and intravenous test.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Investigators plan to study 24 obese patients already enrolled for Roux-en-y gastric bypass
      surgery (RYGB). 8 with type 2 diabetes (DM2), 8 with impaired glucose tolerance (IGT) and 8
      with normal glucose tolerance (NGT) before, within the first week and 3 month after RYGB
      using a liquid mixed meal test (MMT) and an insulin modified frequently sampled intravenous
      glucose tolerance test (IM-FSIGT). Furthermore, an oral glucose tolerance test (OGTT) will be
      performed before and after 3 months. Blood will be sampled in fasting and during the tests
      measuring plasma glucose, insulin and C-peptid (OGTT, MMT and IM-FSIGT) and GLP-1, glucagon,
      GIP and GLP-2 (MMT). Beta-cell function will be assessed from the MMT (insulinogenic index -
      IGI), OGTT (IGI) and the IM-FSIGT (Acute insulin response, AIR) in order to examine whether
      changes in beta-cell function after RYGB depend on an oral stimulus. Insulin sensitivity will
      be assessed in fasting (HOMA-IR), during the IM-FSIGT (minimal model: Si) and from MMT/OGTT
      (Matsuda index). Insulin clearance/hepatic extraction of insulin will be assessed in fasting
      and during the intravenous and oral test.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2010</start_date>
  <completion_date type="Anticipated">June 2014</completion_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in beta-cell function after RYGB.</measure>
    <time_frame>1 week and 3 months.</time_frame>
    <description>Beta-cell function will be assessed with both intravenous tests (acute insulin response to glucose - AIRg) and oral tests (insulinogenic index - IGI).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in insulin sensitivity after RYGB.</measure>
    <time_frame>1 week and 3 months.</time_frame>
    <description>Insulin sensitivity will be assessed in fasting and by intravenous tests (sensitivity index - Si) and oral tests (Matsuda index).</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in glucagon and gastrointestinal hormone secretion after RYGB.</measure>
    <time_frame>1 week and 3 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in insulin clearance after RYGB.</measure>
    <time_frame>1 week and 3 months</time_frame>
  </other_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Type 2 Diabetes</condition>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>RYGB patients with type 2 diabetes</arm_group_label>
    <description>Preoperative oral glucose tolerance test with 2 h P-glucose &gt;11.1 mmol/L</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RYGB patients with IGT</arm_group_label>
    <description>Preoperative oral glucose tolerance test with 2 h p-glucose &gt;7.8 and &lt;11.1 mmol/L</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RYGB patients with NGT</arm_group_label>
    <description>Preoperative oral glucose tolerance test with 2 h p-Glucose &lt;7.8 mmol/L</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum and plasma.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Morbid obese patients who are already enrolled for Roux-en-y gastric bypass surgery will be
        invited to participate (investigators do not assign patients to the surgery). 8 with type 2
        diabetes, 8 with impaired glucose tolerance and 8 with normal glucose tolerance. Glucose
        tolerance will be assessed with an oral glucose tolerance test (OGTT) prior to surgery and
        prior to the other tests. Plasma glucose 120 minutes after OGTT will define glucose
        tolerance. Normal: &lt; 7,8 mM. Impaired: 7,8 - 11,1 mM. Diabetic: &gt;11,1 mM.

        Subjects are recruited from the outpatient clinic of endocrinology and gastrosurgical
        clinic at Hvidovre University Hospital.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients eligible for RYGB, Age 18-60 years, BMI 35-60 kg/m2 at time of referral to
             operation, blood pressure &lt;145/85, C-peptid&gt;700 pmol/l.

        Exclusion Criteria:

          -  Obesity caused by medical treatment for psychiatric disease. Mental retardation.
             Alcohol or drug abuse. Severe cardiopulmonary disease. History of peritonitis,
             ventricular disease, upper gastrointestinal surgery, recurrent oesophagitis or severe
             complications to general anesthesia. Bad compliance. Treatment with thyroid hormones
             or antithyroid treatment. Treatment with anorectic medicine later than 3 months prior
             to surgery. Furthermore prior to surgery each patient has to loose 8 % of bodyweight
             to reduce the risk of operative complications.

        Before each test day all glucose lowering medication will be paused for an appropriate
        amount of time depending on the type of medicine.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anna Kirstine Bojsen-Moeller, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hvidovre University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anna Kirstine Bojsen-Møller, MD</last_name>
    <phone>+45 30 25 22 06</phone>
    <email>kirstine.bojsen-moeller@regionh.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Christoffer Martinussen, student</last_name>
    <phone>+45 22 44 55 30</phone>
    <email>hjz387@alumni.ku.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hvidovre University Hospital</name>
      <address>
        <city>Copenhagen</city>
        <state>Hvidovre</state>
        <zip>2650</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Kirstine Bojsen-Møller, MD</last_name>
      <phone>+45 30 25 22 06</phone>
      <email>kirstine.bojsen-moeller@regionh.dk</email>
    </contact>
    <investigator>
      <last_name>Anna Kirstine Bojsen-Møller, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 12, 2013</study_first_submitted>
  <study_first_submitted_qc>November 20, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 25, 2013</study_first_posted>
  <last_update_submitted>November 20, 2013</last_update_submitted>
  <last_update_submitted_qc>November 20, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 25, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hvidovre University Hospital</investigator_affiliation>
    <investigator_full_name>Anna Kirstine Bojsen-Moeller</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

